Pramipexole (Mirapex) for Parkinson's Disease
Also known as: Mirapex, Sifrol
A dopamine agonist that directly stimulates D2/D3 receptors, used as monotherapy in early PD or adjunct to levodopa in advanced disease.
Mechanism of Action
Pramipexole is a non-ergot dopamine agonist with high affinity for D3 receptors (in the mesolimbic system) and moderate affinity for D2 receptors (in the nigrostriatal pathway). D3 selectivity may contribute to its antidepressant effects. It also has potential neuroprotective properties through ROS scavenging and mitochondrial membrane stabilization.
General mechanism: Non-ergot dopamine agonist with D2/D3 receptor selectivity. Direct post-synaptic dopamine receptor stimulation.
Current Evidence
Effective for early PD motor symptoms and as levodopa adjunct. The CALM-PD trial showed delayed motor complication onset vs. immediate levodopa. Extended-release formulation (Mirapex ER) improves convenience and steady-state levels.
Clinical Status: FDA-approved for Parkinson's and restless legs syndrome. Generic available. Extended-release formulation available.
Safety Profile
Somnolence, sleep attacks, impulse control disorders (gambling, hypersexuality, compulsive shopping), nausea, orthostatic hypotension. Impulse control risk requires monitoring.
Key Research Questions
- Do pramipexole's potential neuroprotective effects translate to disease modification?
- What is the optimal transition strategy from pramipexole monotherapy to levodopa combination?
- Can D3-selective agonism treat PD-associated depression more effectively?